Stub

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the HemOnc Ontology and for historic interest.

Contents


Regimens composed solely of approved drugs

3M

back to top

3M: Mitomycin, Mitoxantrone, Methotrexate

Regimen

Chemotherapy

5-FU & RT

back to top

Regimen

Chemotherapy

Radiotherapy

7+3i & Clofarabine

back to top

7+3i & Clofarabine: 7 days of cytarabine, 3 days of idarubicin, Clofarabine

Regimen

Chemotherapy

7+3i & Lenalidomide

back to top

7+3i & Lenalidomide: 7 days of cytarabine, 3 days of idarubicin, Lenalidomide

Regimen

Chemotherapy

Targeted therapy

7+4i

back to top

7+4i: 7 days of cytarabine, 4 days of idarubicin

Regimen

Chemotherapy

7+5d

back to top

7+5d: 7 days of cytarabine, 5 days of daunorubicin

Regimen

Chemotherapy

Abiraterone & Enzalutamide

back to top

Regimen

Endocrine therapy

ABVP

back to top

Regimen

Chemotherapy

ACP

back to top

ACP: Atezolizumab, Carboplatin, Paclitaxel

Regimen

Immunotherapy

Chemotherapy

Afatinib & Vinorelbine

back to top

Regimen

Chemotherapy

Targeted therapy

A-ICE

back to top

A-ICE: ATRA, Idarubicin, Cytarabine, Etoposide

Regimen

Targeted therapy

Chemotherapy

AME

back to top

AME: Ara-C (Cytarabine), Mitoxantrone, Etoposide

Regimen

Chemotherapy

Amsacrine & IDAC

back to top

Amsacrine & IDAC: Amsacrine & Intermediate Dose Ara-C (Cytarabine)

Regimen

Chemotherapy

ATRA, Cytarabine, Etoposide

back to top

Regimen

Targeted therapy

Chemotherapy

AVML

back to top

Regimen

Chemotherapy

Supportive therapy

Binimetinib monotherapy

back to top

Regimen

Targeted therapy

Bortezomib & Bevacizumab

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
White et al. 2012 (AMBER) 2007-2009 Randomized Phase II (E-esc) Bortezomib Did not meet primary endpoint of PFS
(HR 0.74, 95% CI 0.43-1.28)

Targeted therapy

Bortezomib & Siltuximab

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Orlowski et al. 2015 (CR012784) 2006-2009 Randomized Phase II (E-esc) Bortezomib Did not meet primary endpoint of PFS
(HR 0.87, 95% CI 0.65-1.16)

Targeted therapy

BTH (Taxotere)

back to top

BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)

Regimen

Chemotherapy

Targeted therapy

BTOC

back to top

BTOC: BCNU, Thiotepa, Oncovin (Vincristine), Cyclophosphamide

Regimen

Chemotherapy

CAD

back to top

CAD: Cyclophosphamide, Adriamycin (Doxorubicin), DDP (Cisplatin)

Regimen

Chemotherapy

Capecitabine & Cisplatin (CX) & Bevacizumab

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Cisplatin (CX) & Ramucirumab

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Ruxolitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Sorafenib

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Sunitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Vinflunine

back to top

Regimen

Chemotherapy

Capecitabine & Vinorelbine

back to top

NX: Navelbine (Vinorelbine) & Xeloda (Capecitabine)

Regimen

Chemotherapy

Capecitabine, Cisplatin, Cetuximab, RT

back to top

Regimen

Chemotherapy

Targeted therapy

Radiotherapy

Capecitabine, Erlotinib, RT

back to top

Regimen

Chemotherapy

Targeted therapy

Radiotherapy

CarboMIP

back to top

CarboMIP: Carboplatin, Mitomycin, Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

Carboplatin & Epirubicin

back to top

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Bexarotene

back to top

CP & Bexarotene: Carboplatin, Paclitaxel, Bexarotene

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Cetuximab

back to top

CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Erlotinib

back to top

CP & Erlotinib: Carboplatin, Paclitaxel, Erlotinib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & PLD

back to top

TC & PLD: Taxol (Paclitaxel), Carboplatin, Pegylated Liposomal Doxorubicin

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Sorafenib

back to top

CP & Sorafenib: Carboplatin, Paclitaxel, Sorafenib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Topotecan

back to top

TC & Topotecan: Taxol (Paclitaxel), Carboplatin, Topotecan

Regimen

Chemotherapy

Carboplatin & Topotecan

back to top

Regimen

Chemotherapy

CBM

back to top

CBM: Capecitabine, Bevacizumab, Mitomycin

Regimen

Chemotherapy

Targeted therapy

CCG

back to top

CCG: Cisplatin, Carboplatin, Gemcitabine

Regimen

Chemotherapy

Carboplatin & Etoposide (CE) & Ipilimumab

back to top

CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab

Regimen

Chemotherapy

Immunotherapy

Carboplatin & Etoposide (CE) & Thalidomide

back to top

CE & Thalidomide: Carboplatin, Etoposide, Thalidomide

Regimen

Chemotherapy

Targeted therapy

CIB

back to top

CIB: Cisplatin, Ifosfamide, Bleomycin

Regimen

Chemotherapy

Cisplatin & Methotrexate

back to top

Regimen

Chemotherapy

Cisplatin & Treosulfan

back to top

Regimen

Chemotherapy

Cisplatin & Vincristine

back to top

Regimen

Chemotherapy

Cisplatin, Avelumab, RT

back to top

Regimen

Chemotherapy

Immunotherapy

Radiotherapy

Cisplatin, Pemetrexed, RT

back to top

Regimen

Chemotherapy

Radiotherapy

CODE

back to top

CODE: Cisplatin, Oncovin (Vincristine), Doxorubicin, Etoposide

Regimen

Chemotherapy

CYVADIC

back to top

CYVADIC: CYclophosphamide, Vincristine, ADriamycin (Doxorubicin), Imidazole Carboxamide (Dacarbazine)

Regimen

Chemotherapy

DBCT

back to top

DBCT: Dacarbazine, BCNU (Carmustine), Cisplatin, Tamoxifen

Regimen

Chemotherapy

Endocrine therapy

Docetaxel & Gefitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Lapatinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Pertuzumab

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Selumetinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Sunitinib

back to top

Regimen

Chemotherapy

Targeted therapy

Docetaxel & ziv-Aflibercept

back to top

Regimen

Chemotherapy

Targeted therapy

Doxorubicin & Etoposide

back to top

Regimen

Chemotherapy

Doxorubicin & Paclitaxel

back to top

Regimen

Chemotherapy

Doxorubicin & Sorafenib

back to top

Regimen

Chemotherapy

Targeted therapy

Doxorubicin & Streptozocin

back to top

Regimen

Chemotherapy

Doxorubicin & Vinorelbine

back to top

Regimen

Chemotherapy

EAP

back to top

EAP: Etoposide, Adriamycin (Doxorubicin), Platinol (Cisplatin)

Regimen

Chemotherapy

ECVBP

back to top

ECVBP: Epirubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone

Regimen

Chemotherapy

ELF

back to top

ELF: Etoposide, Leucovorin, 5-FU

Regimen

Chemotherapy

Encorafenib monotherapy

back to top

Regimen

Targeted therapy

EP & Ipilimumab

back to top

EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab

Regimen

Chemotherapy

Immunotherapy

EP, Tamoxifen, RT

back to top

EP, Tamoxifen, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy

Regimen

Chemotherapy

Endocrine therapy

Radiotherapy

Erlotinib & Sunitinib

back to top

Regimen

Targeted therapy

Everolimus & Vinorelbine

back to top

Regimen

Chemotherapy

Targeted therapy

E-GEMOX

back to top

E-GEMOX: Erlotinib, GEMcitabine, OXaliplatin

Regimen

Targeted therapy

Chemotherapy

FAP

back to top

FAP: Fluorouracil, Alfa interferon, Platinol (Cisplatin)

Regimen

Chemotherapy

Immunotherapy

FEC & HP

back to top

FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab

Regimen

Chemotherapy

Targeted therapy

FLA

back to top

FLA: FLudarabine & Ara-C (Cytarabine)

Regimen

Chemotherapy

FLAG-Ida & GO

back to top

FLAG-Ida & GO: FLudarabine, Ara-C (Cytarabine), G-CSF (Lenograstim), Idarubicin, Gemtuzumab Ozogamicin

Regimen

Chemotherapy

Growth factor therapy

Targeted therapy

FLAI

back to top

FLAI: FLudarabine, Ara-C (Cytarabine), Idarubicin
FIA: Fludarabine, Idarubicin, Ara-C (Cytarabine)

Regimen

Chemotherapy

FOLF-CB

back to top

FOLF-CB: FOLinic acid, Fluorouracil, Cetuximab, Bevacizumab

Regimen

Chemotherapy

Targeted therapy

FOLFIRI & Regorafenib

back to top

FOLFIRI & Regorafenib: FOLinic acid, Fluorouracil, IRInotecan, Regorafenib

Regimen

Chemotherapy

Targeted therapy

FOLFIRI & Simvastatin

back to top

FOLFIRI & Simvastatin: FOLinic acid, Fluorouracil, IRInotecan, Simvastatin

Regimen

Chemotherapy

Targeted therapy

FOLFIRI & Sunitinib

back to top

FOLFIRI & Sunitinib: FOLinic acid, Fluorouracil, IRInotecan, Sunitinib

Regimen

Chemotherapy

Targeted therapy

FULV & Trimetrexate

back to top

FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate

Regimen

Chemotherapy

GVP

back to top

GVP: Gemcitabine, Vinorelbine, Platinol (Cisplatin)

Regimen

Chemotherapy

ICE, ATRA, GO

back to top

ICE, ATRA: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid, Gemtuzumab Ozogamicin

Regimen

Chemotherapy

Targeted therapy

Ixabepilone & Bevacizumab

back to top

Regimen

Chemotherapy

Targeted therapy

ME

back to top

ME: Mitoxantrone & Etoposide

Regimen

Chemotherapy

MEV

back to top

MEV: Mitomycin, Etoposide, Vindesine

Regimen

Chemotherapy

MFL

back to top

MFL: Methyl-lomustine (MeCCNU), 5-FU, Leucovorin (Folinic acid)

Regimen

Chemotherapy

MFT

back to top

MFL: Methotrexate, 5-FU, Tamoxifen

Regimen

Chemotherapy

Endocrine therapy

Mitoxantrone & Hydrocortisone

back to top

Regimen

Chemotherapy

Endocrine therapy

MMF

back to top

MMF: Methyl-lomustine (MeCCNU), Mitomycin, 5-FU

Regimen

Chemotherapy

MPP

back to top

MPP: Melphalan, Prednisone, Procarbazine

Regimen

Chemotherapy

MTP

back to top

MTP: Myocet (Non-pegylated liposomal doxorubicin), Trastuzumab, Paclitaxel

Regimen

Chemotherapy

Targeted therapy

MVC

back to top

MVC: Mitomycin, Vindesine, Carboplatin

Regimen

Chemotherapy

NIP

back to top

NIP: Navelbine (Vinorelbine), Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

PD & Pembrolizumab

back to top

PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Mateos et al. 2019 (KEYNOTE-183) 2016-2017 Phase III (E-esc) PD Seems to have inferior PFS
(HR 1.53, 95% CI 1.05-2.22)

Targeted therapy

Chemotherapy

Immunotherapy

PEI

back to top

PEI: Platinol (Cisplatin), Etoposide, Ifosfamide

Regimen

Chemotherapy

PELF

back to top

PELF: Platinol (Cisplatin), Epirubicin, Leucovorin, 5-FU

Regimen

Chemotherapy

PGT

back to top

PGT: Platinol (Cisplatin), Gemcitabine, Taxol (Paclitaxel)

Regimen

Chemotherapy

PGV

back to top

PGV: Platinol (Cisplatin), Gemcitabine, Vinorelbine
CGV: Cisplatin, Gemcitabine, Vinorelbine

Regimen

Chemotherapy

Pemetrexed & Cetuximab

back to top

Regimen

Chemotherapy

Targeted therapy

Pemetrexed & Vandetanib

back to top

Regimen

Chemotherapy

Targeted therapy

Pixantrone & Rituximab

back to top

Regimen

Chemotherapy

Targeted therapy

PVI

back to top

PVI: Platinol (Cisplatin), Vindesine, Ifosfamide
VIP: Vindesine, Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

R-BEACOPP

R-BEACOPP: Rituximab, Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen

Targeted therapy

Chemotherapy

R-MegaCHOEP

back to top

R-MegaCHOEP: Rituximab, high-dose (Mega) Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone

Targeted therapy

Chemotherapy

Realgar-Indigo naturalis formula monotherapy

back to top

Regimen

Targeted therapy

TCG

back to top

TCG: Taxol (Paclitaxel), Carboplatin, Gemcitabine

Regimen

Chemotherapy

TCHL (Taxotere)

back to top

TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib

Regimen

Chemotherapy

Targeted therapy

TCL (Taxotere)

back to top

TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib

Regimen

Chemotherapy

Targeted therapy

TEC

back to top

TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin

Regimen

Chemotherapy

TG+Bev

back to top

TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab

Regimen

Chemotherapy

Targeted therapy

TH (Taxol) & Everolimus

back to top

TH & Everolimus: Taxol (Paclitaxel), Herceptin (Trastuzumab), Everolimus

Regimen

Chemotherapy

Targeted therapy

TL (Taxotere)

back to top

TL: Taxotere (Docetaxel) & Lapatinib

Regimen

Chemotherapy

Targeted therapy

TPCV

back to top

TPCV: Thioguanine, Procarbazine, CCNU, Vincristine

Regimen

Chemotherapy

TX+Bev

back to top

TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab

Regimen

Chemotherapy

Targeted therapy

VADx

back to top

VADx: Vincristine, Ara-C (Cytarabine), Dexamethasone

Regimen

Chemotherapy

VAPEC-B

back to top

VAPEC-B: Vincristine, Adriamycin (Doxorubicin), Prednisolone, Etoposide, Cyclophosphamide, Bleomycin

Regimen

Chemotherapy

VBM (Vinblastine)

back to top

VBM: Vinblastine, Bleomycin, Methotrexate

Regimen

Chemotherapy

VCE

back to top

VCE: Vincristine, Carboplatin, Etoposide

Regimen

Chemotherapy

Vinorelbine & Hydrocortisone

back to top

Regimen

Chemotherapy

Endocrine therapy

VNC

back to top

VNC: Vincristine, Novantrone (Mitoxantrone), Cyclophosphamide

Regimen

Chemotherapy

VPV

back to top

VPV: Vinblastine, Platinol (Cisplatin), VP-16 (Etoposide)

Regimen

Chemotherapy

VTDC

back to top

VTDC: Velcade (Bortezomib), Thalidomide, Dexamethasone, Cyclophosphamide

Regimen

Targeted therapy

Chemotherapy

Regimens that contain experimental (unapproved) drugs

Adavosertib & Gemcitabine

back to top

Regimen

Targeted therapy

Chemotherapy

Alisertib monotherapy

back to top

Regimen

Targeted therapy

Amonafide & Cytarabine

back to top

Regimen

Chemotherapy

Buparlisib & Fulvestrant

back to top

Regimen

Targeted therapy

Endocrine therapy

Buparlisib & Paclitaxel

back to top

Regimen

Targeted therapy

Chemotherapy

Carboplatin & Paclitaxel (CP) & Cediranib

back to top

CP & Cediranib: Carboplatin, Paclitaxel, Cediranib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Trebananib

back to top

TC & Trebananib: Taxol (Paclitaxel), Carboplatin, Trebananib

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Vergote et al. 2019 (TRINOVA-3) 2012-2014 Phase III (E-esc) TC Did not meet primary endpoint of PFS
(HR 0.93, 95% CI 0.79-1.09)

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Veliparib

back to top

CP & Veliparib: Carboplatin, Paclitaxel, Veliparib

Regimen

Chemotherapy

Targeted therapy

Cediranib monotherapy

back to top

Regimen

Targeted therapy

Docetaxel & Bavituximab

back to top

Regimen

Chemotherapy

Immunotherapy

Docetaxel & Ganetespib

back to top

Regimen

Chemotherapy

Targeted therapy

Erlotinib & Figitumumab

back to top

Regimen

Targeted therapy

Erlotinib & Onartuzumab

back to top

Regimen

Targeted therapy

Erlotinib & Tivantinib

back to top

Regimen

Targeted therapy

Cisplatin & Gemcitabine (GC) & Veliparib

back to top

GC & Veliparib: Gemcitabine, Cisplatin, Veliparib

Regimen

Chemotherapy

Targeted therapy

Ibrutinib & Ublituximab

back to top

Regimen

Targeted therapy

PLD & Trebananib

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Marth et al. 2016 (TRINOVA-2) 2011-2013 Phase III (E-esc) PLD Did not meet primary endpoint of PFS
(HR 0.92, 95% CI 0.68-1.24)

Chemotherapy

Targeted therapy